Novo Holdings leads US$50 million investment in South Asia–based MedGenome
BANGALORE, INDIA – FOSTER CITY, USA – SINGAPORE – 30 August 2022 – Novo Holdings A/S (“Novo Holdings” and “NH”), a leading international investor in healthcare and life sciences, today announces it has led a $50 million investment into MedGenome, a leading genetic diagnostics, research and data company, alongside its existing investors, LeapFrog Investments and Sofina. The investment will give Novo Holdings a significant minority stake in MedGenome, and Dr Amit Kakar, Senior Partner, and Navjeewan Khosla, Principal, will join the Board of MedGenome, as Director and Observer, respectively.
